

63
cancel administering a pharmaceutical composition which comprises a therapeutically effective amount of an anti-TWEAK polypeptide monoclonal antibody and a pharmaceutically acceptable carrier.

64 4. (Amended) The method according to claim 1, wherein the animal is mammalian.

12. (Amended) The method according to claim 1, wherein said Graft-Versus-Host Disease or said organ transplant failure is caused by a Th1 cell-mediated immune response.

65 13. (Amended) The method according to claim 1, wherein said Graft-Versus-Host Disease or said organ transplant failure is caused by a Th2 cell-mediated immune response.

14. (Amended) The method according to claim 1, wherein said Graft-Versus-Host Disease or said organ transplant failure is caused by a combination of a Th1 and a Th2 cell-mediated immune response.

Please add the following claim:

23. (Added) The method according to claim 1, wherein said anti-TWEAK polypeptide monoclonal antibody is selected from the group consisting of:

- 66*
- (a) a chimeric antibody;
 - (b) a humanized antibody; and
 - (c) a recombinant antibody.
-